311 related articles for article (PubMed ID: 33595131)
1. Bisphosphonate nephropathy: A case series and review of the literature.
de Roij van Zuijdewijn C; van Dorp W; Florquin S; Roelofs J; Verburgh K
Br J Clin Pharmacol; 2021 Sep; 87(9):3485-3491. PubMed ID: 33595131
[TBL] [Abstract][Full Text] [Related]
2. Bisphosphonates in multiple myeloma: a network meta-analysis.
Mhaskar R; Redzepovic J; Wheatley K; Clark OA; Miladinovic B; Glasmacher A; Kumar A; Djulbegovic B
Cochrane Database Syst Rev; 2012 May; (5):CD003188. PubMed ID: 22592688
[TBL] [Abstract][Full Text] [Related]
3. Bisphosphonate nephrotoxicity.
Perazella MA; Markowitz GS
Kidney Int; 2008 Dec; 74(11):1385-93. PubMed ID: 18685574
[TBL] [Abstract][Full Text] [Related]
4. [Bisphosphonate-induced collapsing focal segmental glomerulosclerosis; two clinical cases and literature review].
Jotterand V; Moll S; Martin PY; Saudan P
Nephrol Ther; 2009 Apr; 5(2):134-8. PubMed ID: 19013118
[TBL] [Abstract][Full Text] [Related]
5. In vitro toxicity of bisphosphonates on human neuroblastoma cell lines.
Vorotnjak M; Boos J; Lanvers-Kaminsky C
Anticancer Drugs; 2004 Sep; 15(8):795-802. PubMed ID: 15494642
[TBL] [Abstract][Full Text] [Related]
6. An audit to determine the time taken to administer intravenous bisphosphonate infusions in patients diagnosed with metastatic breast cancer to bone in a hospital setting.
Barrett-Lee P; Bloomfield D; Dougherty L; Harries M; Laing R; Patel H; Walker M
Curr Med Res Opin; 2007 Jul; 23(7):1575-82. PubMed ID: 17559749
[TBL] [Abstract][Full Text] [Related]
7. Bisphosphonates for breast cancer.
Pavlakis N; Schmidt R; Stockler M
Cochrane Database Syst Rev; 2005 Jul; (3):CD003474. PubMed ID: 16034900
[TBL] [Abstract][Full Text] [Related]
8. Distinct mechanisms of bisphosphonate action between osteoblasts and breast cancer cells: identity of a potent new bisphosphonate analogue.
Reinholz GG; Getz B; Sanders ES; Karpeisky MY; Padyukova NSh; Mikhailov SN; Ingle JN; Spelsberg TC
Breast Cancer Res Treat; 2002 Feb; 71(3):257-68. PubMed ID: 12002344
[TBL] [Abstract][Full Text] [Related]
9. Toxic acute tubular necrosis following treatment with zoledronate (Zometa).
Markowitz GS; Fine PL; Stack JI; Kunis CL; Radhakrishnan J; Palecki W; Park J; Nasr SH; Hoh S; Siegel DS; D'Agati VD
Kidney Int; 2003 Jul; 64(1):281-9. PubMed ID: 12787420
[TBL] [Abstract][Full Text] [Related]
10. Ocular Side Effects of Bisphosphonates: A Review of Literature.
Chartrand NA; Lau CK; Parsons MT; Handlon JJ; Ronquillo YC; Hoopes PC; Moshirfar M
J Ocul Pharmacol Ther; 2023; 39(1):3-16. PubMed ID: 36409537
[TBL] [Abstract][Full Text] [Related]
11. Comparison of different intravenous bisphosphonate regimens for Paget's disease of bone.
Merlotti D; Gennari L; Martini G; Valleggi F; De Paola V; Avanzati A; Nuti R
J Bone Miner Res; 2007 Oct; 22(10):1510-7. PubMed ID: 17605632
[TBL] [Abstract][Full Text] [Related]
12. Renal complications from bisphosphonate treatment.
Hirschberg R
Curr Opin Support Palliat Care; 2012 Sep; 6(3):342-7. PubMed ID: 22710581
[TBL] [Abstract][Full Text] [Related]
13. Highly potent geminal bisphosphonates. From pamidronate disodium (Aredia) to zoledronic acid (Zometa).
Widler L; Jaeggi KA; Glatt M; Müller K; Bachmann R; Bisping M; Born AR; Cortesi R; Guiglia G; Jeker H; Klein R; Ramseier U; Schmid J; Schreiber G; Seltenmeyer Y; Green JR
J Med Chem; 2002 Aug; 45(17):3721-38. PubMed ID: 12166945
[TBL] [Abstract][Full Text] [Related]
14. Bisphosphonates and osteonecrosis of the jaw: a retrospective study.
Murad OM; Arora S; Farag AF; Guber HA
Endocr Pract; 2007; 13(3):232-8. PubMed ID: 17599853
[TBL] [Abstract][Full Text] [Related]
15. Zoledronate and pamidronate depress neutrophil functions and survival in mice.
Kuiper JW; Forster C; Sun C; Peel S; Glogauer M
Br J Pharmacol; 2012 Jan; 165(2):532-9. PubMed ID: 21745192
[TBL] [Abstract][Full Text] [Related]
16. In vitro effects of bisphosphonates on chemotaxis, phagocytosis, and oxidative burst of neutrophil granulocytes.
Hagelauer N; Pabst AM; Ziebart T; Ulbrich H; Walter C
Clin Oral Investig; 2015 Jan; 19(1):139-48. PubMed ID: 24668343
[TBL] [Abstract][Full Text] [Related]
17. Novel therapy to reverse the cellular effects of bisphosphonates on primary human oral fibroblasts.
Cozin M; Pinker BM; Solemani K; Zuniga JM; Dadaian SC; Cremers S; Landesberg R; Raghavan S
J Oral Maxillofac Surg; 2011 Oct; 69(10):2564-78. PubMed ID: 21807448
[TBL] [Abstract][Full Text] [Related]
18. Bisphosphonates in breast cancer.
Coleman RE
Ann Oncol; 2005 May; 16(5):687-95. PubMed ID: 15802276
[TBL] [Abstract][Full Text] [Related]
19. Current management strategies for hypercalcemia.
Pecherstorfer M; Brenner K; Zojer N
Treat Endocrinol; 2003; 2(4):273-92. PubMed ID: 15966562
[TBL] [Abstract][Full Text] [Related]
20. Bisphosphonates: restrictions for vasculogenesis and angiogenesis: inhibition of cell function of endothelial progenitor cells and mature endothelial cells in vitro.
Ziebart T; Pabst A; Klein MO; Kämmerer P; Gauss L; Brüllmann D; Al-Nawas B; Walter C
Clin Oral Investig; 2011 Feb; 15(1):105-11. PubMed ID: 20024592
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
